The maker of EpiPens overcharged the Medicaid program for years by misclassifying its product, the Obama administration says.

ADVERTISEMENT

Democratic lawmakers released a letter on Wednesday from Andy Slavitt, head of the Centers for Medicare and Medicaid Services (CMS), confirming that EpiPen maker Mylan had misclassified the device — in effect, overcharging taxpayers for its product.

The revelation is the latest turn involving Mylan, which has recently faced outrage from both parties over its 400 percent-plus increase in the price of EpiPens in the past few years.

The letter from Slavitt, released by Sen. Ron Wyden Ronald (Ron) Lee WydenGOP set to release controversial Biden report Democrats fear Russia interference could spoil bid to retake Senate GOP senator blocks Schumer resolution aimed at Biden probe as tensions run high MORE (D-Ore.) and Rep. Frank Pallone (D-N.J.), confirms that Mylan has misclassified the EpiPen as a generic drug, as opposed to a brand drug, since 1997. That means Mylan was only giving Medicaid a 13 percent discount on its product, instead of a 23.1 percent discount.

The CMS even noted it had specifically told Mylan that its product was misclassified.

“The Center for Medicaid and CHIP Services in CMS has, on multiple occasions, provided guidance to the industry and Mylan on the proper classification of drugs and has expressly told Mylan that the product is incorrectly classified,” Slavitt wrote.

"EpiPen Auto-Injector has been classified as a non-innovator since long before Mylan acquired the product," said Mylan spokeswoman Nina Devlin on Wednesday.

"Mylan’s classification of EpiPen Auto-Injector as a non-innovator drug is consistent with longstanding written guidance from the federal government."

The CMS declined to comment on whether it has taken steps to correct this misclassification and recover the money Mylan owes to Medicaid.

However, the CMS did note broadly that companies that misclassify their products can be held liable under the False Claims Act.

“Today’s letter is more evidence that while Mylan irresponsibly raised the price of EpiPen, they were also bilking taxpayers out of millions of dollars,” Wyden and Pallone said in a statement.

“Essential medicines like EpiPen are increasingly out of reach for families across the nation due to unjustified price hikes, and it’s high time for drug companies to take responsibility for their actions. We will ensure taxpayers get their due.”

Updated 5:36 p.m.